Interestingly since VEGF is produced by Schwannoma tumor cells, systemic bevacizumab therapy has been in the management of vestibular schwannomas in neurofibromatosis type 2 [68, 69] but further research is warranted to evaluate anti-VEGF therapy in NF1. The gene discussed is VEGFA; the disease is NF2-related schwannomatosis.